A
Andrew Norton
Researcher at Harvard University
Publications - 4
Citations - 2382
Andrew Norton is an academic researcher from Harvard University. The author has contributed to research in topics: Flow network & Network packet. The author has an hindex of 1, co-authored 4 publications receiving 2286 citations.
Papers
More filters
Journal ArticleDOI
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
Margaret A. Shipp,Kenneth N. Ross,Pablo Tamayo,Andrew P. Weng,Jeffery L. Kutok,Ricardo C.T. Aguiar,Michelle Gaasenbeek,Michael Angelo,Michael R. Reich,Geraldine S. Pinkus,Tane S. Ray,Margaret A. Koval,Andrew Norton,T. Andrew Lister,Jill P. Mesirov,Donna Neuberg,Eric S. Lander,Jon C. Aster,Todd R. Golub +18 more
TL;DR: Genes implicated in DLBCL outcome included some that regulate responses to B-cell–receptor signaling, critical serine/threonine phosphorylation pathways and apoptosis, and identify rational targets for intervention.
Proceedings ArticleDOI
FPGA-Driven Table System to Accelerate Network Flows
TL;DR: The principal design goal is to achieve FPGA-level speed when processing tables for flows, actions, packet modification, key search and hash extraction and yet to allow users to initialize and dynamically modify the tables in terms of flexible, high-level packetC language types and structures.
High-Dose T herapy W ith A utologous B one M arrow S upport as C onsolidation o f R emission i n F ollicular L ymphoma: Long-Term C linical a nd M olecular F ollow-Up
John Apostolidis,R. K. Gupta,Demetrios Grenzelias,Vassiliki Pappa,Karin E. Summers,Ashiq Salam,K. Adams,Andrew Norton,Janet Matthews,Mike Bradburn,T. Andrew Lister +10 more
Presentation S erum S elenium P redicts f or O verall S urvival, Dose D elivery, a nd F irst T reatment R esponse i n A ggressive Non-Hodgkin's L ymphoma
Victoria Cornelius,Trevor Delves,Christine Sieniawska,Jude Fitzgibbon,Andrew Norton,J. A. L. Amess,Andrew Wilson,T. Andrew Lister +7 more
TL;DR: Serum selenium concentration at presentation is a prognostic factor, predicting positively for dose delivery, treatment response, and long-term survival in aggressive non-Hodgkin’s lymphoma.